Darolutamide API CAS 1297538-32-9

Darolutamide API is a new generation of non-steroidal androgen receptor-targeting active substance. With its unique molecular structure and highly selective mechanism of action, it has become a valuable novel compound in the treatment of andrological tumors. This substance possesses excellent targeted binding ability, precisely and competitively binding to androgen receptors within the body. It effectively blocks the interaction between endogenous hormones and receptors, while simultaneously inhibiting receptor transport to the cell nucleus and binding to gene fragments. This blocks the proliferation signaling of related abnormal cells at the source, smoothly regulating related physiological pathways and slowing the progression and spread of abnormal tissues.

It has low blood-brain barrier penetration, significantly reducing interference with the central nervous system compared to similar active ingredients. Overall, it is more mildly tolerated and less likely to cause cognitive impairment, nervous excitement, or other adverse reactions. During daily use, mild fatigue, limb soreness, and slight skin reactions are commonly observed. Minor fluctuations in metabolic indicators are occasional, indicating a high overall safety profile. It also has minimal interference with metabolic enzymes and good compatibility when used in combination with other auxiliary conditioning ingredients.